1 DNA Way Mailstop 258A
South San Francisco
About Genentech, Inc.
1633 articles with Genentech, Inc.
The American Diabetes Association and Genentech Partner to Increase Equitable Access to Eye Health Care
The American Diabetes Association® and Genentech, a member of the Roche Group, announced a new partnership as part of the ADA's Health Equity Now work to tackle access to screening and treatment for eye diseases that affect the diabetes community.
An independent panel of advisers voted to approve Genentech's Polivy after internal FDA staff raised concerns regarding the efficacy and risk-benefit profile as a first-line treatment for large B-cell lymphoma.
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 in favor of Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).
FDA Action Alert: Roche and Acadia
3/6/2023The FDA's Oncologic Drugs Advisory Committee will meet March 9 to discuss Roche's sBLA for Polivy in first-line DLBCL, while Acadia awaits potential approval of the first therapy for Rett Syndrome.
New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)
Genentech, a member of the Roche Group, announced positive new data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® in macular edema due to branch and central retinal vein occlusion at 24 weeks.
Data from a Phase III study show Genentech’s crovalimab is non-inferior to AstraZeneca’s Soliris, the current standard of care in paroxysmal nocturnal hemoglobinuria (PNH).
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
Genentech, a member of the Roche Group, announced positive results from the global Phase III COMMODORE 2 study, evaluating the efficacy and safety of crovalimab in people with paroxysmal nocturnal hemoglobinuria who have not been previously treated with complement inhibitors.
Roche's Tecentriq (atezolizumab) combined with Avastin (bevacizumab) met the primary efficacy endpoint in early-stage hepatocellular carcinoma in the Phase III IMbrave050 study.
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
Genentech, a member of the Roche Group, announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival at the prespecified interim analysis.
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
Kronos Bio, Inc. (Nasdaq: KRON) announced today that it has entered into a discovery collaboration in the field of oncology with Genentech, a member of the Roche Group, focused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech.
Belharra Launches with $130M From Versant, Genentech to Advance Chemoproteomics Platform (Updated)
1/4/2023Backed by Versant and Genentech, Belharra Therapeutics launched Wednesday with $130 million in total financing to advance its novel chemoproteomics platform.
Belharra Therapeutics Announces Broad Collaboration with Genentech to Discover and Develop Novel Medicines Across Multiple Therapeutic Areas
Belharra Therapeutics today announced a multi-year collaboration with Genentech, a member of the Roche Group.
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Lunsumio® for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
Genentech today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab).
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
Biogen Inc. (Nasdaq: BIIB) announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab.
Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that updated clinical data for its CD20xCD3 T-cell engaging bispecific antibodies, including five oral presentations, were presented at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, December 10-13, 2022.
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
Genentech, a member of the Roche Group, announced interim results from the Phase III HAVEN 7 study.
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
Genentech, a member of the Roche Group, announced that new and updated data for its first-in-class anti-CD79b antibody-drug conjugate Polivy® were presented at the 64th American Society of Hematology Annual Meeting & Exposition, December 10-13.
As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody, Tecentriq, for metastatic bladder cancer.